left-caret
Insights

attorney authored

Considerations for Innovator Drug Companies Regarding China’s Drug Patent Linkage System - 中国将施行药品专利链接制度——创新药企应如何应变

December 01, 2020

By Bruce M. Wexler, Melanie R. Rupert, Mi Zhou, Mark Sperling, & Jake A. Silvers

This article originally appeared in IP Economy magazine.

On June 1, 2021, China will implement a drug patent linkage system that will allow drug companies to resolve patent infringement disputes before the marketing approval of competitor drugs in China.  Paul Hastings’ Global IP Co-Chair Bruce Wexler, Partner Melanie Rupert, and IP associates Mi Zhou, Mark Russell Sperling, and Jake Silvers, offer considerations for innovator drug companies in this rapidly developing area.  A reprint is available at the link below.


Click here for a PDF of the full text

Contributors

Image: Bruce M. Wexler
Bruce M. Wexler
Partner, Litigation Department

Image: Melanie R. Rupert
Melanie R. Rupert
Partner, Litigation Department

Image: Mi Zhou
Mi Zhou
Associate, Litigation Department

Image: Mark Sperling
Mark Sperling
Associate, Litigation Department

Image: Jake A. Silvers
Jake A. Silvers
Associate, Litigation Department

Practice Areas


For More Information

Image: Melanie R. Rupert
Melanie R. Rupert
Partner, Litigation Department
Image: Bruce M. Wexler
Bruce M. Wexler
Partner, Litigation Department
Image: Mark Sperling
Mark Sperling
Associate, Litigation Department
Image: Mi Zhou
Mi Zhou
Associate, Litigation Department